GlassScriptPhysician profile
Athira Jayan
NPI 1578192209
$3,398.42
in general payments reported to CMS, 2019-2025
36 companies · $2,165 in 2025
The $2,165 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.87 · 2023: $17.32 · 2024: $1,203 · 2025: $2,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,287 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,286.55 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $333.20 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Alexion Pharmaceuticals, INC. | $293.97 | 2023-2025 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $277.84 | 2024-2025 | Imfinzi |
| Abbvie INC. | $264.74 | 2024-2025 | |
| Caris Mpi, INC. | $222.14 | 2025 | Mi Cancer Seek |
| Eisai INC. | $170.58 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $169.97 | 2025 | |
| Sobi, INC | $164.74 | 2024-2025 | |
| Incyte Corporation | $164.06 | 2024-2025 | Jakafi |
| Amgen INC. | $143.20 | 2024 | |
| Pharmaessentia USA Corporation | $124.25 | 2025 | Besremi |
| Daiichi Sankyo INC. | $101.03 | 2024-2025 | Enhertu, Vanflyta, Datroway |
| Genzyme Corporation | $96.83 | 2024-2025 | |
| Tersera Therapeutics LLC | $73.15 | 2025 | Zoladex |
| Takeda Pharmaceuticals U.S.A., INC. | $67.70 | 2024-2025 | Fruzaqla, Alunbrig |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $62.30 | 2025 | Tevimbra |
| Genentech USA, INC. | $62.15 | 2025 | Venclexta, Phesgo, Itovebi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.93 | 2025 | |
| Deciphera Pharmaceuticals INC. | $57.06 | 2024-2025 | Qinlock, Romvimza |
| Blueprint Medicines Corporation | $56.04 | 2024-2025 | Ayvakit |
| Pfizer INC. | $48.69 | 2021-2025 | |
| Agios Pharmaceuticals, INC. | $41.81 | 2024-2025 | Pyrukynd |
| Glaxosmithkline, LLC. | $33.55 | 2025 | Jemperli, Zejula |
| Csl Behring | $33.08 | 2024-2025 | Idelvion, Afstyla |
| Taiho Oncology, INC. | $29.94 | 2024 | |
| Stemline Therapeutics INC. | $28.28 | 2025 | Orserdu |
| Beigene USA, INC. | $27.58 | 2024 | Brukinsa |
| Genmab U.S., INC. | $24.67 | 2025 | Epkinly |
| Geron Corporation | $24.19 | 2025 | Rytelo |
| Emd Serono, INC. | $21.12 | 2025 | |
| Lilly USA, LLC | $21.05 | 2024 | Jaypirca, Verzenio |
| Puma Biotechnology, INC. | $20.98 | 2024 | |
| Recordati_rare_diseases_inc. | $20.94 | 2025 | Enjaymo |
| Bayer Healthcare Pharmaceuticals INC. | $20.85 | 2025 | |
| Kyowa Kirin, INC. | $18.00 | 2025 | |
| Array Biopharma INC | $16.81 | 2025 | Mektovi, Lorbrena, Xalkori |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Athira Jayan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.